Targeting GM-CSF in inflammatory diseases

Nature Reviews Rheumatology

Volumn 12, Issue 1, 2016, Pages 37-48

  Wicks, Ian P ^a   Roberts, Andrew W ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR ALPHA; MAVRILIMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KB003; MONOCLONAL ANTIBODY MOR103; MONOCLONAL ANTIBODY MORAB 002; NAMILUMAB; PLACEBO; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; SIGNAL PEPTIDE;

AORTA ANEURYSM; ARTHRITIS; ARTICLE; ASTHMA; B LYMPHOCYTE; COLITIS; DENDRITIC CELL; DRUG EFFICACY; DRUG TOLERABILITY; EOSINOPHIL; GOUT; HUMAN; INTERSTITIAL LUNG DISEASE; MACROPHAGE; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; OSTEOARTHRITIS; PAIN; PLEURISY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SENSORY NERVE CELL; SINGLE DRUG DOSE; T LYMPHOCYTE; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; RHEUMATIC DISEASES; SYNOVIAL FLUID;

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGES; RHEUMATIC DISEASES; SYNOVIAL FLUID;

EID: 84954198071     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.161     Document Type: Article

References (157)

1. Metcalf, D. Hematopoietic cytokines. Blood 111, 485-491 (2008).
2. Metcalf, D. The colony-stimulating factors and cancer. Nat. Rev. Cancer 10, 425-434 (2010).
3. Williamson, D. J., Begley, C. G., Vadas, M. A. & Metcalf, D. The detection and initial characterization of colony-stimulating factors in synovial fluid. Clin. Exp. Immunol. 72, 67-73 (1988).
4. Xu, W. D., Firestein, G. S., Taetle, R., Kaushansky, K. & Zvaifler, N. J. Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J. Clin. Invest. 83, 876-882 (1989).
5. Cornish, A. L., Campbell, I. K., McKenzie, B. S., Chatfield, S. & Wicks, I. P. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat. Rev. Rheumatol 5, 554-559 (2009).
6. Hamilton, J. A. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8, 533-544 (2008).
7. Shiomi, A. & Usui, T. Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm. 2015, 568543 (2015).
8. LeVine, A. M., Reed, J. A., Kurak, K. E., Cianciolo, E. & Whitsett, J. A. GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. J. Clin. Invest. 103, 563-569 (1999).
9. Stosser, S., Schweizerhof, M. & Kuner, R. Hematopoietic colony-stimulating factors: new players in tumor-nerve interactions. J. Mol. Med. (Berl.) 89, 321-329 (2011).
10. Broughton, S. E. et al. The c receptor family-structural insights and their functional implications. Cytokine 74, 247-258 (2015).
11. Hercus, T. R. et al. Signalling by the c family of cytokines. Cytokine Growth Factor Rev. 24, 189-201 (2013).
12. Guthridge, M. A. & Lopez, A. F. Phosphotyrosine/phosphoserine binary switches: a new paradigm for the regulation of PI3K signalling and growth factor pleiotropy Biochem. Soc. Trans. 35, 250-252 (2007).
13. Liontos, L. M. et al. The Src-like adaptor protein regulates GM-CSFR signaling and monocytic dendritic cell maturation. J. Immunol. 186, 1923-1933 (2011).
14. Bunda, S., Kommaraju, K., Heir, P. & Ohh, M. SOCS-1 mediates ubiquitylation and degradation of GM-CSF receptor. PLoS ONE 8, e76370 (2013).
15. Metcalf, D. et al. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia 13, 926-934 (1999).
16. Wright, H. L., Thomas, H. B., Moots, R. J. & Edwards, S. W. RNA-seq reveals activation of both common and cytokine-specific pathways following neutrophil priming. PLoS ONE 8, e58598 (2013).
17. Cowburn, A. S. et al. Granulocyte/macrophage colony-stimulating factor causes a paradoxical increase in the BH3-only pro-apoptotic protein Bim in human neutrophils. Am. J. Respir. Cell. Mol. Biol. 44, 879-887 (2011).
18. Eyles, J. L., Roberts, A. W., Metcalf, D. & Wicks, I. P. Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease. Nat. Clin. Pract. Rheumatol. 2, 500-510 (2006).
19. Yong, K. L., Rowles, P. M., Patterson, K. G. & Linch, D. C. Granulocyte-macrophage colony-stimulating factor induces neutrophil adhesion to pulmonary vascular endothelium in vivo: role of beta 2 integrins. Blood 80, 1565-1575 (1992).
20. Kolaczkowska, E. & Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13, 159-175 (2013).
21. Futosi, K., Fodor, S. & Mocsai, A. Neutrophil cell surface receptors and their intracellular signal transduction pathways. Int. Immunopharmacol. 17, 638-650 (2013).
22. Yousefi, S., Mihalache, C., Kozlowski, E., Schmid, I. & Simon, H. U. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. Cell Death Differ. 16, 1438-1444 (2009).
23. Goldmann, O. & Medina, E. The expanding world of extracellular traps: not only neutrophils but much more. Front. Immunol. 3, 420 (2012).
24. Curran, C. S. & Bertics, P. J. Lactoferrin regulates an axis involving CD11b and CD49d integrins and the chemokines MIP-1 and MCP-1 in GM-CSF-treated human primary eosinophils. J. Interferon Cytokine Res. 32, 450-461 (2012).
25. Wong, C. K. et al. MicroRNA-21 regulates the prosurvival effect of GM-CSF on human eosinophils. Immunobiology 218, 255-262 (2013).
26. Liu, L. Y., Wang, H., Xenakis, J. J. & Spencer, L. A. Notch signaling mediates granulocyte-macrophage colony-stimulating factor priming-induced transendothelial migration of human eosinophils. Allergy 70, 805-812 (2015).
27. Hamilton, J. A. & Achuthan, A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol. 34, 81-89 (2013).
28. Mantovani, A., Sica, A. & Locati, M. Macrophage polarization comes of age. Immunity 23, 344-346 (2005).
29. Guilliams, M. & van de Laar, L. A. Hitchhiker's guide to myeloid cell subsets: practical implementation of a novel mononuclear phagocyte classification system. Front. Immunol. 6, 406 (2015).
30. Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14-20 (2014).
31. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969 (2008).
32. Fleetwood, A. J., Dinh, H., Cook, A. D., Hertzog, P. J. & Hamilton, J. A. GM-CSF-and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J. Leukoc. Biol. 86, 411-421 (2009).
33. Akagawa, K. S. et al. Functional heterogeneity of colony-stimulating factor-induced human monocyte-derived macrophages. Respirology 11, S32-S36 (2006).
34. Joshi, S. et al. Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. PLoS ONE 9, e95893 (2014).
35. Martinez, F. O., Gordon, S., Locati, M. & Mantovani, A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177, 7303-7311 (2006).
36. Shibata, Y. et al. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 15, 557-567 (2001).
37. Krausgruber, T. et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12, 231-238 (2011).
38. Sierra-Filardi, E. et al. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 117, 5092-5101 (2011).
39. Su, X. et al. Interferon-regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nat. Immunol. 16, 838-849 (2015).
40. Stanley, E. et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl Acad. Sci. USA 91, 5592-5596 (1994).
41. Louis, C. et al. Specific contributions of CSF-1 and GM-CSF to the dynamics of the mononuclear phagocyte system. J. Immunol. 195, 134-144 (2015).
42. Dai, X. M. et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99, 111-120 (2002).
43. Varol, C., Mildner, A. & Jung, S. Macrophages: development and tissue specialization. Annu. Rev. Immunol. 33, 643-675 (2015).
44. Wang, Y. et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat. Immunol. 13, 753-760 (2012).
45. Hashimoto, D. et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38, 792-804 (2013).
46. Guilliams, M. et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J. Exp. Med. 210, 1977-1992 (2013).
47. Schneider, C. et al. Induction of the nuclear receptor PPAR-by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. Nat. Immunol. 15, 1026-1037 (2014).
48. Sakagami, T. et al. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N. Engl. J. Med. 361, 2679-2681 (2009).
49. Bain, C. C. et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat. Immunol. 15, 929-937 (2014).
50. Misharin, A. V. et al. Nonclassical Ly6C-monocytes drive the development of inflammatory arthritis in mice. Cell Rep. 9, 591-604 (2014).
51. Tak, P. P. & Bresnihan, B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 43, 2619-2633 (2000).
52. Hamilton, J. A. & Tak, P. P. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum. 60, 1210-1221 (2009).
53. Schlitzer, A. & Ginhoux, F. Organisation of the mouse and human DC network. Curr. Opin. Immunol. 26, 90-99 (2014).
54. King, I. L., Kroenke, M. A. & Segal, B. M. GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J. Exp. Med. 207, 953-961 (2010).
55. Hirata, Y., Egea, L., Dann, S. M., Eckmann, L. & Kagnoff, M. F. GM-CSF-facilitated dendritic cell recruitment and survival govern the intestinal mucosal response to a mouse enteric bacterial pathogen. Cell Host Microbe 7, 151-163 (2010).
56. Dabritz, J. Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G455-G465 (2014).
57. Zhan, Y. et al. GM-CSF increases cross-presentation and CD103 expression by mouse CD8+ spleen dendritic cells. Eur. J. Immunol. 41, 2585-2595 (2011).
58. Zhan, Y., Xu, Y. & Lew, A. M. The regulation of the development and function of dendritic cell subsets by GM-CSF: more than a hematopoietic growth factor. Mol. Immunol. 52, 30-37 (2012).
59. Esashi, E. et al. The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity 28, 509-520 (2008).
60. Gonzalez-Juarrero, M. et al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J. Leukoc. Biol. 77, 914-922 (2005).
61. Riopel, J., Tam, M., Mohan, K., Marino, M. W. & Stevenson, M. M. Granulocyte-macrophage colony-stimulating factor-deficient mice have impaired resistance to blood-stage malaria. Infect. Immun. 69, 129-136 (2001).
62. Paine, R. et al. Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice. J. Immunol. 164, 2602-2609 (2000).
63. Grau, G. E., Kindler, V., Piguet, P. F., Lambert, P. H. & Vassalli, P. Prevention of experimental cerebral malaria by anticytokine antibodies. Interleukin 3 and granulocyte macrophage colony-stimulating factor are intermediates in increased tumor necrosis factor production and macrophage accumulation. J. Exp. Med. 168, 1499-1504 (1988).
64. Campbell, I. K. et al. Differentiation of inflammatory dendritic cells is mediated by NF-B1-dependent GM-CSF production in CD4 T cells. J. Immunol. 186, 5468-5477 (2011).
65. Naik, S. H. et al. Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat. Immunol. 7, 663-671 (2006).
66. Segura, E. & Amigorena, S. Inflammatory dendritic cells in mice and humans. Trends Immunol. 34, 440-445 (2013).
67. Segura, E. et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 38, 336-348 (2013).
68. Caux, C. et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF. J. Exp. Med. 184, 695-706 (1996).
69. Xu, Y., Zhan, Y., Lew, A. M., Naik, S. H. & Kershaw, M. H. Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J. Immunol. 179, 7577-7584 (2007).
70. van Nieuwenhuijze, A. E. et al. Transgenic expression of GM-CSF in T cells causes disseminated histiocytosis. Am. J. Pathol. 184, 184-199 (2014).
71. Fleetwood, A. J., Lawrence, T., Hamilton, J. A. & Cook, A. D. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J. Immunol. 178, 5245-5252 (2007).
72. Ko, H. J. et al. GM-CSF-responsive monocyte-derived dendritic cells are pivotal in Th17 pathogenesis. J. Immunol. 192, 2202-2209 (2014).
73. Jiao, Z. et al. The closely related CD103+ dendritic cells (DCs) and lymphoid-resident CD8+ DCs differ in their inflammatory functions. PLoS ONE 9, e91126 (2014).
74. Wang, J. et al. Transgenic expression of granulocyte-macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung. Blood 95, 2337-2345 (2000).
75. Teng, M. W. et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21, 719-729 (2015).
76. Codarri, L. et al. RORt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12, 560-567 (2011).
77. Ruan, Q. et al. The Th17 immune response is controlled by the Rel-ROR-RORT transcriptional axis. J. Exp. Med. 208, 2321-2333 (2011).
78. Jeltsch, K. M. et al. Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote TH17 differentiation. Nat. Immunol. 15, 1079-1089 (2014).
79. Man, K. et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat. Immunol. 14, 1155-1165 (2013).
80. Sheng, W. et al. STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation. Cell Res. 24, 1387-1402 (2014).
81. Noster, R. et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci. Transl. Med. 6, 241-80 (2014).
82. Bar, E., Whitney, P. G., Moor, K., Reis e Sousa, C. & LeibundGut-Landmann, S. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity 40, 117-127 (2014).
83. Campbell, I. K. et al. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J. Immunol. 161, 3639-3644 (1998).
84. Yang, Y. H. & Hamilton, J. A. Dependence of interleukin-1-induced arthritis on granulocyte-macrophage colony-stimulating factor. Arthritis Rheum. 44, 111-119 (2001).
85. Lawlor, K. E., Campbell, I. K., O'Donnell, K., Wu, L. & Wicks, I. P. Molecular and cellular mediators of interleukin-1-dependent acute inflammatory arthritis. Arthritis Rheum. 44, 442-450 (2001).
86. Plater-Zyberk, C. et al. GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann. Rheum. Dis. 66, 452-457 (2007).
87. Sonderegger, I. et al. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J. Exp. Med. 205, 2281-2294 (2008).
88. El-Behi, M. et al. The encephalitogenicity of TH17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 12, 568-575 (2011).
89. van Nieuwenhuijze, A. et al. GM-CSF as a therapeutic target in inflammatory diseases. Mol. Immunol. 56, 675-682 (2013).
90. Egan, P. J., van Nieuwenhuijze, A., Campbell, I. K. & Wicks, I. P. Promotion of the local differentiation of murine Th17 cells by synovial macrophages during acute inflammatory arthritis. Arthritis Rheum. 58, 3720-3729 (2008).
91. Greter, M. et al. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 36, 1031-1046 (2012).
92. Croxford, A. L. et al. The cytokine GM-CSF drives the inflammatory signature of CCR2+ monocytes and licenses autoimmunity. Immunity 43, 502-514 (2015).
93. Rauch, P. J. et al. Innate response activator B cells protect against microbial sepsis. Science 335, 597-601 (2012).
94. Weber, G. F. et al. Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis. J. Exp. Med. 211, 1243-1256 (2014).
95. Wang, M. et al. Interleukin-3/granulocyte macrophage colony-stimulating factor receptor promotes stem cell expansion, monocytosis, and atheroma macrophage burden in mice with hematopoietic ApoE deficiency. Arterioscler. Thromb. Vasc. Biol. 34, 976-984 (2014).
96. Hilgendorf, I. et al. Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity. Circulation 129, 1677-1687 (2014).
97. Van Doornum, S., McColl, G. & Wicks, I. P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis Arthritis Rheum. 46, 862-873 (2002).
98. Uchida, K. et al. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 113, 2547-2556 (2009).
99. Browne, S. K. & Holland, S. M. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect. Dis. 10, 875-885 (2010).
100. Piccoli, L. et al. Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat. Commun. 6, 7375 (2015).
101. de la Rubia, J. et al. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Bone Marrow Transplant. 24, 723-728 (1999).
102. Schweizerhof, M. et al. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat. Med. 15, 802-807 (2009).
103. Cook, A. D. et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain. Ann. Rheum. Dis. 72, 265-270 (2013).
104. Cook, A. D. et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res. Ther. 14, R199 (2012).
105. Fiehn, C., Wermann, M., Pezzutto, A., Hufner, M. & Heilig, B. Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy. Z. Rheumatol. 51, 121-126 (in German) (1992).
106. Field, M. & Clinton, L. Expression of GM-CSF receptor in rheumatoid arthritis. Lancet 342, 1244 (1993).
107. Hazenberg, B. P., Van Leeuwen, M. A., Van Rijswijk, M. H., Stern, A. C. & Vellenga, E. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 74, 2769-2770 (1989).
108. Okada, Y. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376-381 (2014).
109. Alvaro-Gracia, J. M., Zvaifler, N. J., Brown, C. B., Kaushansky, K. & Firestein, G. S. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J. Immunol. 146, 3365-3371 (1991).
110. Campbell, I. K., Novak, U., Cebon, J., Layton, J. E. & Hamilton, J. A. Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1. J. Immunol. 147, 1238-1246 (1991).
111. Cook, A. D., Braine, E. L., Campbell, I. K., Rich, M. J. & Hamilton, J. A. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 3, 293-298 (2001).
112. Plater-Zyberk, C. et al. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor-independent mouse model. Ann. Rheum. Dis. 68, 721-728 (2009).
113. van Nieuwenhuijze, A. E. et al. Complementary action of granulocyte-macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-B ligand and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis. Arthritis es. Ther. 17, 163 (2015).
114. Shaw, O. M., Steiger, S., Liu, X., Hamilton, J. A. & Harper, J. L. Brief report: granulocyte-macrophage colony-stimulating factor drives monosodium urate monohydrate crystal-induced inflammatory macrophage differentiation and NLRP3 inflammasome up-regulation in an in vivo mouse model. Arthritis Rheumatol. 66, 2423-2428 (2014).
115. Ponomarev, E. D. et al. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J. Immunol. 178, 39-48 (2007).
116. King, I. L., Dickendesher, T. L. & Segal, B. M. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 113, 3190-3197 (2009).
117. Carrieri, P. B. et al. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol. Immunotoxicol. 20, 373-382 (1998).
118. McQualter, J. L. et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J. Exp. Med. 194, 873-882 (2001).
119. Haak, S. et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 119, 61-69 (2009).
120. Benham, H. et al. Interleukin-23 mediates the intestinal response to microbial-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol. 66, 1755-1767 (2014).
121. Shiomi, A. et al. GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. J. Immunol. 193, 849-859 (2014).
122. Willart, M. A. et al. Interleukin-1 controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J. Exp. Med. 209, 1505-1517 (2012).
123. Vlahos, R. et al. Neutralizing granulocyte/macrophage colony-stimulating factor inhibits cigarette smoke-induced lung inflammation. Am. J. Respir. Crit. Care Med. 182, 34-40 (2010).
124. Botelho, F. M. et al. A mouse GM-CSF receptor antibody attenuates neutrophilia in mice exposed to cigarette smoke. Eur. Respir. J. 38, 285-294 (2011).
125. Yamashita, N. et al. Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF). Cell. Immunol. 219, 92-97 (2002).
126. Fahy, J. V. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc. Am. Thorac Soc. 6, 256-259 (2009).
127. Griseri, T. et al. Granulocyte macrophage colony-stimulating factor-activated eosinophils promote interleukin-23 driven chronic colitis. Immunity 43, 187-199 (2015).
128. Son, B. K. et al. Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural haematoma. Nat. Commun. 6, 6994 (2015).
129. Mellak, S. et al. Angiotensin II mobilizes spleen monocytes to promote the development of abdominal aortic aneurysm in Apoe/mice. Arterioscler. Thromb. Vasc. Biol. 35, 378-388 (2015).
130. Chen, L. et al. IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology. Mucosal Immunol. 8, 390-402 (2015).
131. Dabritz, J. et al. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am. J. Gastroenterol. 108, 1901-1910 (2013).
132. Gearing, D. P., King, J. A., Gough, N. M. & Nicola, N. A. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO J. 8, 3667-3676 (1989).
133. Ryan, P. C. et al. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety. Toxicol. Appl. Pharmacol. 279, 230-239 (2014).
134. Liang, M. et al. Internalization of the antibody (CAM-3001) following monocyte cell surface binding to the GM-CSFR alpha chain. American College of Rheumatology [online], https://acr.confex.com/acr/2008/webprogram/Paper3891.html (2008).
135. Greven, D. E. et al. Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis. Ann. Rheum. Dis. 74, 1924-1930 (2014).
136. Burmester, G. R. et al. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, Phase I, first-in-human study. Ann. Rheum. Dis. 70, 1542-1549 (2011).
137. Burmester, G. R. et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann. Rheum. Dis. 72, 1445-1452 (2013).
138. Curtis, J. R. et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res. (Hoboken) 64, 1794-1803 (2012).
139. Takeuchi, T. et al. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study. Mod. Rheumatol 25, 21-30 (2015).
140. McInnes, I. B. et al. Rapid onset of clinical benefit is associated with a reduction in validated biomarkers of disease in patients with rheumatoid arthritis treated with mavrilimumab, a monoclonal antibody targeting GM-CSFR. ACRabstracts [online], http://acrabstracts.org/abstract/rapid-onset-of-clinical-benefit-is-associated-with-a-reduction-in-validated-biomarkers-of-disease-in-patients-with-rheumatoid-arthritis-treated-with-mavrilimumab-a-human-monoclonal-antibody-targeting (2014).
141. Burmester, G. et al. Efficacy and safety of mavrilimumab, a fully human GMCSFR alpha monoclonal antibody in patients with rheumatoid arthritis: primary results from the earth explorer 1 study. Ann. Rheum. Dis. Abstr. 74, 78 (2015).
142. Steidl, S., Ratsch, O., Brocks, B., Durr, M. & Thomassen-Wolf, E. In vitro affinity maturation of human GMCSF antibodies by targeted CDRdiversification. Mol. Immunol. 46, 135-144 (2008).
143. Behrens, F. et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colonystimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a Phase Ib/IIa randomised, double-blind, placebocontrolled, dose-escalation trial. Ann. Rheum. Dis. 74, 1058-1064 (2015).
144. US National Library of Medicine. A Phase 1 MT203 single-dose study to evaluate safety, PK and PD. Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02354599 (2015).
145. US National Library of Medicine. A Trial to evaluate the safety and tolerability of namilumab (MT203) in patients with mild to moderate rheumatoid arthritis (PRIORA). Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01317797 (2015).
146. US National Library of Medicine. Efficacy and safety of namilumab (MT203) for plaque psoriasis. Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02129777 (2015).
147. US National Library of Medicine. Namilumab vs adalimumab in participants with moderate to severe early rheumatoid arthritis inadequately responding to methotrexate (TELLUS). Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02393378 (2015).
148. US National Library of Medicine. Dose finding study of namilumab in combination with methotrexate in participants with moderate to severe rheumatoid arthritis (RA). Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02379091 (2015).
149. US National Library of Medicine. Safety and preliminary efficacy of MOR103 in patients with active rheumatoid arthritis. Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01023256 (2014).
150. US National Library of Medicine. Phase Ib study to evaluate MOR103 in multiple sclerosis. Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01517282 (2014).
151. US National Library of Medicine. Effect of KB003 in subjects with asthma inadequately controlled by corticosteroids (KB003-04). Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01603277 (2015).
152. US National Library of Medicine. Study of KB003 in previously treated patients with chronic myelomonocytic leukemia (CMML). Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02546284 (2015).
153. US National Library of Medicine. Safety and tolerability of MORAb-022 in healthy and rheumatoid arthritis subjects. Clinicaltrials.gov [online], https://clinicaltrials. gov/ct2/show/NCT01357759 (2015).
154. US National Library of Medicine. A single dose study of the CAM-3001 in patients with rheumatoid arthritis. Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00771420 (2012).
155. US National Library of Medicine. A study to evaluate the efficacy and safety of CAM-3001 (drug) in subjects with rheumatoid arthritis. Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01050998 (2014).
156. US National Library of Medicine. A study of mavrilimumab versus anti tumor necrosis factor in subjects with rheumatoid arthritis. Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01715896 (2015).
157. US National Library of Medicine. A study of mavrilimumab in subjects with moderate-to-severe rheumatoid arthritis. Clinicaltrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01706926 (2014).